护心康片治疗冠心病不稳定型心绞痛临床疗效及对肿瘤坏死因子-α和N端脑钠肽的影响  

Clinical Efficacy of Huxinkang Pills on Patients with Unstable Angina Pectoris and Effects on Tumor Necrosis Factor-α and N-terminal Pro-brain Natriuretic Peptide

作　　者：王国倩[1] 喻敏成 喻正科[1] 陈志红[1] 谢洪途[3] 

机构地区：[1]湖南省中医药研究院附属医院,湖南长沙410006 [2]南昌大学医学院第一临床学院,江西南昌330006 [3]空军预警学院,湖北武汉430019

出　　处：《中国中医药信息杂志》2016年第3期16-19,共4页Chinese Journal of Information on Traditional Chinese Medicine

基　　金：湖南省科研计划项目(201115)

摘　　要：目的观察护心康片对冠心病不稳定型心绞痛(UAP)患者的疗效及对肿瘤坏死因子-α(TNF-α)和N端脑钠肽(NT-pro BNP)的影响。方法将60例UAP患者随机分为治疗组和对照组各30例,均给予常规西药治疗,治疗组加服护心康片,对照组加服通心络胶囊,疗程4周。观察2组患者临床疗效及治疗前后TNF-α和NT-pro BNP水平变化。结果 2组综合疗效、心电图疗效、心绞痛疗效、中医证候疗效和硝酸甘油停减情况组间比较差异均有统计学意义(P<0.05),治疗组优于对照组。TNF-α和NT-pro BNP水平,组内治疗前后比较差异均有统计学意义(P<0.05),治疗后组间比较差异均有统计学意义(P<0.05),治疗组优于对照组。结论护心康片治疗UAP患者疗效显著,能有效降低TNF-α和NT-pro BNP水平。Objective To observe the clinical efficacy of Huxinkang Pills in treating patients with unstable angina pectoris (UAP) and its effects on the tumor necrosis factor-α (TNF-α) and N-terminal pro-brain natriuretic peptide (NT-proBNP). Methods Sixty patients with UAP were randomly divided into the treatment group and the control group, 30 cases in each group. Patients in the treatment group were treated with Huxinkang Pills based on the basic western medicine, while the patients in the control group were treated with Tongxinluo Capsules based on the basic western medicine. The treatment course was 4 weeks. Clinical efficacy and the change of the TNF-α and NT-proBNP levels before and after treatment were observed. Results The general efficacy, electrocardiograph efficacy, angina pectoris efficacy, TCM syndrome efficacy and glonoine reduction of the two groups had statistically difference (P<0.05) respectively, and the efficacy of the treatment group was superior to that of the control group (P<0.05). The TNF-α and NT-proBNP levels in both groups before and after treatment had statistically difference (P<0.05) respectively. The differences in TNF-α and NT-proBNP levels between both groups after treatment were all statistically significant (P<0.05), and these indexes of treatment group were superior to those of the control group (P<0.05). Conclusion Huxinkang Pills are remarkable in treating patients with UAP, and able to restrain the levels of TNF-α and NT-proBNP.

关 键 词：冠心病 不稳定型心绞痛 护心康片 肿瘤坏死因子-Α N端脑钠肽 

分 类 号：R259.414.2[医药卫生—中西医结合]